Reciprocal activating crosstalk between c-Met and caveolin 1 promotes invasive phenotype in hepatocellular carcinoma

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Korhan, Peyda ^a   Erdal, Esra ^a   Kandemiş, Emine ^a   Çokakli, Murat ^a   Nart, Deniz ^b   Yilmaz, Funda ^b   Can, Alp ^c   Atabey, Neşe ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b EGE UNIVERSITY   (Turkey)

^c ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; SCATTER FACTOR RECEPTOR; PROTEIN BINDING; SCATTER FACTOR;

ARTICLE; BIOLOGICAL ACTIVITY; BRANCHING MORPHOGENESIS; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE INTERACTION; GENE LOCATION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR INTERACTION; PHENOTYPIC VARIATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR INVASION; AGONISTS; ANTAGONISTS AND INHIBITORS; CELL MOTION; DRUG EFFECTS; GENETICS; LIVER CIRRHOSIS; LIVER TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROTEIN TRANSPORT; RNA INTERFERENCE; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; CAVEOLIN 1; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HEPATOCYTE GROWTH FACTOR; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-MET; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84929056210     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105278     Document Type: Article

References (44)

1. Mitchell KA (2013) Hapatocellular carcinoma: Histological considerations: Pure, mixed, and motely. J Clin Gastroenterol doi: 10.1097/MCG. 0b013e318291f237.
2. Van Malenstein H, Van Pelt J, Verslyoe C (2011) Molecular classification of hepatocellular carcinoma anno. Eur J Cancer47:1789-1797.
3. Chan SL, Yeo W (2012) Targeted therapy of hepatocellular carcinoma: present and future. J Gastroenterol Hepatol 27: 862-872.
4. Chua CWL, Choo SP (2011) Targeted therapy in hepatocellular carcinoma. Int J Hepatol 348297.
5. Kondo S, Ojima H, Tsuda H, Hashimoto J, Morizane C, et al (2013) Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma. Int J Clin Oncol 18: 207-213.
6. Venepalli NK, Goff L (2013) Targeting the HGF-cMET axis in hepatocellular carcinoma. Int J Hepatol 341636.
7. Chu JS, Ge FL, Zhang B, Wang Y, Silvestris N, et al (2013) Expression and prognostic value of VEGFR-2, PDGFR-22, and c-Met in advanced hepatocellular carcinoma. J Exp Clin Cancer Res 32: doi: 10.1186/1756-9966-32-16.
8. Gao J, Feng X, Inagaki Y, Song P, Kokudo N, et al (2012) Des-γ-carboxy prothrombin and c-Met were concurrently and extensively expressed in hepatocellular carcinoma and associated with tumor recurrence. Biosci Trends 6: 153-159.
9. Marx-Stoelting P, Borowiak M, Knorpp T, Birchmeier C, Buchmann A, et al (2008) Hepatocarcinogenesis in mice with a conditional knockout of the hepatocyte growth factor receptor c-Met. Int J Cancer 124: 1767-1772.
10. Takami T, Kaposi-Novak P, Uchida K, Gomez-Quiroz LE, Conner EA, et al (2007) Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res 67: 9844-9851. (Pubitemid 47621232)
11. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, et al (2002) Role of the hepatocyte gorwth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 13: 41-59. (Pubitemid 34436961)
12. Nakamura T, Sakai K, Matsumoto K (2011) Hepatocyte growth factor twenty years on: Much more than a growth factor. J Gastroenterol Hepatol 1: 188-202.
13. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, et al (1991) Identification of the hepatocyte growth factor receptor as the c-met protooncogene product. Science 251: 802-804. (Pubitemid 21926175)
14. Lai AZ, Abella JV, Park M (2009) Crosstalk in Met receptor oncogenesis. Trends Cell Biol 19: 542-551.
15. You H, Ding W, Dang H, Jiang Y, Rountree CB (2011) c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology52: 879-889.
16. Gao JJ, Inagaki Y, Xue X, Qu XJ, Tang W (2011) c-Met: A potential therapeutic target for hepatocellular carcinoma. Drug Discov Ther 5: 2-11.
17. Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E (1997) Expression of the hepatocyte growth factor and its receptor proto-oncogene in hepatocellular carcinoma. Hepatology25: 862-866. (Pubitemid 27157127)
18. D'Errico A, Fiorentino M, Ponzetto A, Daikuhara Y, Tsubouchi H, et al (1996) Liver hepatocyte growth factor does not always correlate with hepatocellular proliferation in human liver lesions: its specific receptor c-Met does. Hepatology 24: 60-64. (Pubitemid 26249414)
19. Osada S, Kanematsu M, Imai H, Goshima S (2008) Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. Hepatogastroenterology 55: 544-549. (Pubitemid 351741499)
20. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316: 1039-1043. (Pubitemid 46799492)
21. Yamaguchi H, Chang SS, Hsu JL, Hung MC (2013) Signaling cross-talk in the resistance to HER family receptor targeted therapy. Oncogene doi: 10.1038/onc.2013.74.
22. Coleman D, Bigelow R, Cardelli JA (2009) Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation. Mol Cancer Ther 8: 214-224.
23. Razani B, Woodman SE, Lisanti MP (2002) Caveolae: from cell biology to animal physiology. Pharmacol Rev 54: 431-467.
24. Pike LJ (2005) Growth factor receptors, lipid rafts and caveolae: an evolving story. Biochim Biophys Acta 1746: 260-273.
25. Williams TM, Lisanti M P (2005) Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Ohysiol Cell Physiol 288: 494-506.
26. Cokakli M, Erdal E, Nart D, Yilmaz F, Sagol O, et al (2009) Differential expression of caveolin-1 in hepatocellular carcinoma: correlation with differentiation state, motility and invasion. BMC Cancer doi: 10.1186/1471-2407-9-65.
27. Zhang ZB, Cai L, Zheng SG, Xiong Y, Dong JH (2009) Overexpression of caveolin-1 in hepatocellular carcinoma with metastasis and worse prognosis: correlation with vascular endothelial growth factor, microvessel density and unpaired artery. Pathol Oncol Res 15: 495-502.
28. Tse EY, Tung EK, Chan LK, Lee TK, Ngan ES, et al (2012) Caveolin-1 overexpression is associated with hepatocellular carcinoma tumourigenesis and metastasis. J Pathol226: 645-653.
29. Wang S, Jia L, Zhou H, Shi W, Zhang J (2009) Knockdown of caveolin-1 by siRNA inhibits the transformation of mouse hepatoma H22 cells in vitro and in vivo. Oligonucleotides 19: doi: 10.1089/oli.2008.0166.
30. Yang SF, Yang JY, Huangs CH, Wang SN, Lu CP, et al (2010) Increased caveolin-1 expression associated with prolonged overall survival rate in hepatocellular carcinoma. Pathology 42: 468-445.
31. Bozkaya G, Korhan P, Cokakli M, Erdal E, Sagol O, et al (2012) Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis. Mol Cancer 11: doi: 10.1186/1476-4598-11-64.
32. Atabey N, Gao Y, Yao ZJ, Breckenridge D, Soon L, et al (2001) Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions. J Biol Chem276: 14308-14314.
33. Montesano R, Soriano JV, Malinda KM, Ponce ML, Bafico A, et al (1998) Differential effects of hepatocyte growth factor isoforms on endothelial and endothelial tubulogeneis. Cell Growth Differ 9: 355-365. (Pubitemid 28345875)
34. Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, et al (2009) Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med13: 2673-83.
35. Peters S, Adjei A (2012) A MET a promising anticancer therapeutic target, Nat Rev Clin Oncol 9: 314-26.
36. Mastick CC, Brady MJ, Saltiel AR (1995) Insulin stimulates the tyrosine phosphorylation of caveolin. J Cell Biol 129: 1523-1531.
37. Lee H, Volonte D, Galbiati F, Iyengar P, Lublin DM, et al (2000) Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Mol Endocrinol 14: 1750-1775.
38. Joshi B, Strugnell SS, Goetz JG, Kojic LD, Cox ME, et al (2008) Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res 68: doi: 10.1158/0008-5472. CAN-08-0343.
39. Urra H, Torres VA, Ortiz RJ, Lobos L, Diaz MI, et al (2012) Caveolin-1-enhanced motility and focal adhesion turnover require tyrosine-14 but not accumulation to the rear in metastatic cancer cells. Plos One 7: doi: 10.1371/journal.pone.0033085.
40. Cho KW, Park JH, Park CW, Lee D, Lee E, et al (2013) Identification of a pivotal endocytosis motif in c-Met and selective modulation of HGF-dependent aggressiveness of cancer using the 16-mer endocytic peptide. Oncogene 32: doi: 10.1038/onc.2012.122.
41. Seto E, Bellen HJ, Lloyd TE (2002) When cell biology meets development: endocytic regulation of signaling pathyways. Genes Dev 16: 1314-1336. (Pubitemid 34615085)
42. Le Roy C, Wrana JL (2005) Clathrin- and non-clathrin mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol 6: 112-126. (Pubitemid 40215807)
43. Kermorhant S, Zicha D, Parker PJ (2004) PKC controls HGF-dependent c-Met traffic, signaling and cell migration. EMBO J 2004 23: 3721-3734. (Pubitemid 39389704)
44. Ng YS, Ramasauer M, Loureiero RM, D'Amore PA (2004) Identification of genes involved in VEGF-mediated vascular morphogenesis using embryonic stem cell-derived cystic embryoid bodies. Lab Invest 84: 1209-18.